Ibrutinib and Venetoclax for First-Line Treatment of CLL | Zendy

Nitin Jain | Zendy; Michael J. Keating | Zendy; Philip A. Thompson | Zendy; Alessandra Ferrajoli | Zendy; Jan A. Burger | Zendy; Gautam Borthakur | Zendy; Koichi Takahashi | Zendy; Zeev Estrov | Zendy; Nathan Fowler | Zendy; Tapan M. Kadia | Zendy; Marina Konopleva | Zendy; Yesid Alvarado | Zendy; Musa Yılmaz | Zendy; Courtney D. DiNardo | Zendy; Prithviraj Bose | Zendy; Maro Ohanian | Zendy; Naveen Pemmaraju | Zendy; Elias Jabbour | Zendy; Koji Sasaki | Zendy; Rashmi KanagalShamanna | Zendy; Keyur P. Patel | Zendy; Jeffrey L. Jorgensen | Zendy; Naveen Garg | Zendy; Xuemei Wang | Zendy; Katrina Sondermann | Zendy; Nichole Cruz | Zendy; Chongjuan Wei | Zendy; Ana Ayala | Zendy; William Plunkett | Zendy; Hagop M. Kantarjian | Zendy; Varsha Gandhi | Zendy; William G. Wierda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Author(s) -

Nitin Jain,

Michael J. Keating,

Philip A. Thompson,

Alessandra Ferrajoli,

Jan A. Burger,

Gautam Borthakur,

Koichi Takahashi,

Zeev Estrov,

Nathan Fowler,

Tapan M. Kadia,

Marina Konopleva,

Yesid Alvarado,

Musa Yılmaz,

Courtney D. DiNardo,

Prithviraj Bose,

Maro Ohanian,

Naveen Pemmaraju,

Elias Jabbour,

Koji Sasaki,

Rashmi KanagalShamanna,

Keyur P. Patel,

Jeffrey L. Jorgensen,

Naveen Garg,

Xuemei Wang,

Katrina Sondermann,

Nichole Cruz,

Chongjuan Wei,

Ana Ayala,

William Plunkett,

Hagop M. Kantarjian,

Varsha Gandhi,

William G. Wierda

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1900574

Subject(s) - ibrutinib , venetoclax , chronic lymphocytic leukemia , medicine , bruton's tyrosine kinase , lymphoma , cancer research , leukemia , oncology , tyrosine kinase , receptor

Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research